Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. 2021 Mar 12.
View in:
PubMed
Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Adv. 2021 Feb 09; 5(3):649-661.
View in:
PubMed
RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia. Oncogene. 2021 Jan; 40(4):746-762.
View in:
PubMed
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020 Dec 14; 38(6):872-890.e6.
View in:
PubMed
On Grieving for the Out-of-Practice. N Engl J Med. 2020 Nov 05; 383(19):1809-1811.
View in:
PubMed
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in B cells. Nature. 2020 12; 588(7838):491-497.
View in:
PubMed
Polymerase d promotes chromosomal rearrangements and imprecise double-strand break repair. Proc Natl Acad Sci U S A. 2020 11 03; 117(44):27566-27577.
View in:
PubMed
Signalling input from divergent pathways subverts B cell transformation. Nature. 2020 07; 583(7818):845-851.
View in:
PubMed
DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 07 16; 13(1):95.
View in:
PubMed
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. Cancers (Basel). 2020 Jun 17; 12(6).
View in:
PubMed
Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma. Cell Rep. 2020 05 05; 31(5):107522.
View in:
PubMed
Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions. Blood. 2020 04 23; 135(17):1467-1471.
View in:
PubMed
Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1265-1269.
View in:
PubMed
Breaking Down the Barriers to Define and Treat NK/T Cell Lymphoma. Cancer Cell. 2020 03 16; 37(3):263-265.
View in:
PubMed
Chemical, Biological, Radiological, Nuclear, and Explosive (CBRNE) Science and the CBRNE Science Medical Operations Science Support Expert (CMOSSE). Disaster Med Public Health Prep. 2019 12; 13(5-6):995-1010.
View in:
PubMed
Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Sci Rep. 2019 11 20; 9(1):17161.
View in:
PubMed
Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One. 2019; 14(11):e0221288.
View in:
PubMed
AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. 2020 02 15; 26(4):922-934.
View in:
PubMed
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. J Clin Invest. 2019 11 01; 129(11):5005-5019.
View in:
PubMed
TFH lymphomas: the times they aza-changin'? Blood. 2019 10 24; 134(17):1364-1365.
View in:
PubMed
Targeted inhibition of CD47-SIRPa requires Fc-Fc?R interactions to maximize activity in T-cell lymphomas. Blood. 2019 10 24; 134(17):1430-1440.
View in:
PubMed
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19. Clin Cancer Res. 2019 12 01; 25(23):7046-7057.
View in:
PubMed
Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508.
View in:
PubMed
Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discov. 2019 07; 9(7):944-961.
View in:
PubMed
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019 02 28; 133(9):952-961.
View in:
PubMed
Challenges and implications of genomics for T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):63-68.
View in:
PubMed
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood. 2019 02 07; 133(6):566-575.
View in:
PubMed
Parp3 promotes long-range end joining in murine cells. Proc Natl Acad Sci U S A. 2018 10 02; 115(40):10076-10081.
View in:
PubMed
Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles. Blood. 2018 10 18; 132(16):1695-1702.
View in:
PubMed
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018 10 04; 132(14):1495-1506.
View in:
PubMed
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLoS One. 2018; 13(7):e0199708.
View in:
PubMed
Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. J Invest Dermatol. 2018 11; 138(11):2365-2376.
View in:
PubMed
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.
View in:
PubMed
RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. Blood. 2018 08 30; 132(9):935-947.
View in:
PubMed
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications. Br J Haematol. 2018 06; 181(5):642-652.
View in:
PubMed
B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. Cell. 2018 04 05; 173(2):470-484.e18.
View in:
PubMed
An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia. 2018 09; 32(9):1970-1983.
View in:
PubMed
Targeting minimal residual disease: a path to cure? Nat Rev Cancer. 2018 04; 18(4):255-263.
View in:
PubMed
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia. Oncotarget. 2018 Jan 30; 9(8):8027-8041.
View in:
PubMed
Clinicogenetic risk modeling in ATL. Blood. 2018 01 11; 131(2):159-160.
View in:
PubMed
Activity of the PI3K-d,? inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018 02 22; 131(8):888-898.
View in:
PubMed
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520.
View in:
PubMed
Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. Blood Adv. 2017 Nov 28; 1(25):2361-2374.
View in:
PubMed
PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res. 2017 11 01; 77(21):e62-e66.
View in:
PubMed
A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas. Cell Rep. 2017 Oct 17; 21(3):784-797.
View in:
PubMed
Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in:
PubMed
Cancer models: The next best thing. Nature. 2017 09 07; 549(7670):39-41.
View in:
PubMed
The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017 09 28; 130(13):1491-1498.
View in:
PubMed
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Aug 08; 8(32):52026-52044.
View in:
PubMed
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase. Oncotarget. 2017 Jul 06.
View in:
PubMed
Corrigendum: PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 06 13; 8:15918.
View in:
PubMed
Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. Proc Natl Acad Sci U S A. 2017 06 20; 114(25):6581-6586.
View in:
PubMed
The promise of organ and tissue preservation to transform medicine. Nat Biotechnol. 2017 06 07; 35(6):530-542.
View in:
PubMed
PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. Nat Commun. 2017 04 27; 8:15110.
View in:
PubMed
It Takes a Village to Unmask HSTL. Cancer Discov. 2017 04; 7(4):352-353.
View in:
PubMed
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations. EMBO Mol Med. 2017 04; 9(4):498-507.
View in:
PubMed
Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. Br J Haematol. 2017 04; 177(2):271-282.
View in:
PubMed
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Adv. 2016 Nov 29; 1(1):84-92.
View in:
PubMed
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16.
View in:
PubMed
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024.
View in:
PubMed
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol. 2017 Jan; 35(1):24-31.
View in:
PubMed
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016 11 24; 128(21):2517-2526.
View in:
PubMed
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol. 2016 Nov; 34(11):1161-1167.
View in:
PubMed
High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays. Nat Biotechnol. 2016 Oct; 34(10):1052-1059.
View in:
PubMed
Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones. Oncotarget. 2016 08 09; 7(32):51494-51502.
View in:
PubMed
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016 08 25; 128(8):1112-20.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in:
PubMed
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood. 2016 08 25; 128(8):1093-100.
View in:
PubMed
Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia. 2016 10; 30(10):2112-2116.
View in:
PubMed
Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene. 2016 11 24; 35(47):6077-6086.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in:
PubMed
Buying cures versus renting health: Financing health care with consumer loans. Sci Transl Med. 2016 Feb 24; 8(327):327ps6.
View in:
PubMed
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood. 2016 05 05; 127(18):2203-13.
View in:
PubMed
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016 Jan 26; 14(3):429-439.
View in:
PubMed
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv. 2015 Sep; 1(8):e1500221.
View in:
PubMed
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia. 2016 Jan; 30(1):219-28.
View in:
PubMed
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 Sep; 16(9):1111-1122.
View in:
PubMed
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in:
PubMed
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia. Cell Rep. 2015 Jun 09; 11(9):1446-57.
View in:
PubMed
A roadmap for discovery and translation in lymphoma. Blood. 2015 Mar 26; 125(13):2175-7.
View in:
PubMed
Public health and medical preparedness for a nuclear detonation: the nuclear incident medical enterprise. Health Phys. 2015 Feb; 108(2):149-60.
View in:
PubMed
Mutations in G protein ß subunits promote transformation and kinase inhibitor resistance. Nat Med. 2015 Jan; 21(1):71-5.
View in:
PubMed
Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target. Leuk Lymphoma. 2015 May; 56(5):1524-7.
View in:
PubMed
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol. 2015 Jan; 168(2):230-8.
View in:
PubMed
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2015 Jan; 29(1):237-41.
View in:
PubMed
Ubiquitin-specific peptidase 20 regulates Rad17 stability, checkpoint kinase 1 phosphorylation and DNA repair by homologous recombination. J Biol Chem. 2014 Aug 15; 289(33):22739-22748.
View in:
PubMed
Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
View in:
PubMed
TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. Database (Oxford). 2014; 2014:bau007.
View in:
PubMed
A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014 Feb 27; 123(9):1293-6.
View in:
PubMed
Inactivation of Uaf1 causes defective homologous recombination and early embryonic lethality in mice. Mol Cell Biol. 2013 Nov; 33(22):4360-70.
View in:
PubMed
Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6):e67306.
View in:
PubMed
p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ. 2013 Nov; 20(11):1465-74.
View in:
PubMed
Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling. Cell Commun Signal. 2013 Apr 17; 11(1):27.
View in:
PubMed
PARP1 is required for chromosomal translocations. Blood. 2013 May 23; 121(21):4359-65.
View in:
PubMed
Low frequency clonal mutations recoverable by deep sequencing in patients with aplastic anemia. Leukemia. 2013 Apr; 27(4):968-71.
View in:
PubMed
Medical planning and response for a nuclear detonation: a practical guide. Biosecur Bioterror. 2012 Dec; 10(4):346-71.
View in:
PubMed
Next-generation cDNA screening for oncogene and resistance phenotypes. PLoS One. 2012; 7(11):e49201.
View in:
PubMed
Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2. Blood. 2012 Oct 04; 120(14):2853-63.
View in:
PubMed
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012 Oct 04; 120(14):2843-52.
View in:
PubMed
The evolving contribution of hematopoietic progenitor cells to lymphomagenesis. Blood. 2012 Sep 27; 120(13):2553-61.
View in:
PubMed
BCL2 suppresses PARP1 function and nonapoptotic cell death. Cancer Res. 2012 Aug 15; 72(16):4193-203.
View in:
PubMed
TSLP signaling network revealed by SILAC-based phosphoproteomics. Mol Cell Proteomics. 2012 Jun; 11(6):M112.017764.
View in:
PubMed
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73.
View in:
PubMed
Radiation disasters: role of the BMT team. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S189-92.
View in:
PubMed
Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55.
View in:
PubMed
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems. Disaster Med Public Health Prep. 2011 Oct; 5(3):183-201.
View in:
PubMed
First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation. Disaster Med Public Health Prep. 2011 Oct; 5(3):202-12.
View in:
PubMed
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production. Oncogene. 2012 May 10; 31(19):2491-8.
View in:
PubMed
Planning and response to radiation exposures. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1262-3.
View in:
PubMed
Repair at single targeted DNA double-strand breaks in pluripotent and differentiated human cells. PLoS One. 2011; 6(5):e20514.
View in:
PubMed
Health care system planning for and response to a nuclear detonation. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S73-88.
View in:
PubMed
Scarce resources for nuclear detonation: project overview and challenges. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S13-9.
View in:
PubMed
Medical response to a nuclear detonation: creating a playbook for state and local planners and responders. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S89-97.
View in:
PubMed
Triage and treatment tools for use in a scarce resources-crisis standards of care setting after a nuclear detonation. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S111-21.
View in:
PubMed
Allocation of scarce resources after a nuclear detonation: setting the context. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S20-31.
View in:
PubMed
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S32-44.
View in:
PubMed
Using the model of resource and time-based triage (MORTT) to guide scarce resource allocation in the aftermath of a nuclear detonation. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S98-110.
View in:
PubMed
Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making. Disaster Med Public Health Prep. 2011 Mar; 5 Suppl 1:S46-53.
View in:
PubMed
Radiation injury treatment network (RITN): healthcare professionals preparing for a mass casualty radiological or nuclear incident. Int J Radiat Biol. 2011 Aug; 87(8):748-53.
View in:
PubMed
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell. 2011 Jan 21; 41(2):210-20.
View in:
PubMed
Epstein-Barr virus, lymphoma risk and the potential role of HIV infection in IBD patients undergoing immunosuppression. Dig Dis. 2010; 28(3):519-24.
View in:
PubMed
The p400 ATPase regulates nucleosome stability and chromatin ubiquitination during DNA repair. J Cell Biol. 2010 Oct 04; 191(1):31-43.
View in:
PubMed
t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. Blood. 2010 Sep 16; 116(11):1993-4.
View in:
PubMed
The transposase domain protein Metnase/SETMAR suppresses chromosomal translocations. Cancer Genet Cytogenet. 2010 Jul 15; 200(2):184-90.
View in:
PubMed
Medical management of radiation victims in the United States. Health Phys. 2010 Jun; 98(6):833-7.
View in:
PubMed
Assessing surge capacity for radiation victims with marrow toxicity. Biol Blood Marrow Transplant. 2010 Oct; 16(10):1436-41.
View in:
PubMed
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in:
PubMed
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009 Aug 27; 114(9):1813-9.
View in:
PubMed
Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A. 2009 Jun 30; 106(26):10620-5.
View in:
PubMed
Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop. Stem Cells. 2009 May; 27(5):1205-11.
View in:
PubMed
The evolution of influenza resistance and treatment. JAMA. 2009 Mar 11; 301(10):1066-9.
View in:
PubMed
Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Dev Cell. 2009 Feb; 16(2):314-20.
View in:
PubMed
Hepatitis C virus infection does not preclude standard breast cancer-directed therapy. Clin Breast Cancer. 2009 Feb; 9(1):51-2.
View in:
PubMed
Limited utility of serum galactomannan assay after auto-SCT. Bone Marrow Transplant. 2009 Jul; 44(1):59-61.
View in:
PubMed
A PP4-phosphatase complex dephosphorylates gamma-H2AX generated during DNA replication. Mol Cell. 2008 Jul 11; 31(1):33-46.
View in:
PubMed
Response: Radiologic and nuclear events. Blood. 2008 Jun 15; 111(12):5758-5759.
View in:
PubMed
Limited complications from breast cancer treatment in women with chronic hepatitis C virus infection. J Clin Oncol. 2008 May 20; 26(15_suppl):20745.
View in:
PubMed
Prevalence of late morbidity in survivors of Hodgkin's lymphoma (HL) treated during adulthood. J Clin Oncol. 2008 May 20; 26(15_suppl):9589.
View in:
PubMed
Psychosocial functioning in survivors of Hodgkin lymphoma (HL) treated during adulthood. J Clin Oncol. 2008 May 20; 26(15_suppl):9592.
View in:
PubMed
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. Biol Blood Marrow Transplant. 2008 May; 14(5):595-600.
View in:
PubMed
Radiologic and nuclear events: contingency planning for hematologists/oncologists. Blood. 2008 Jun 15; 111(12):5440-5.
View in:
PubMed
Induction of chromosomal translocations in mouse and human cells using site-specific endonucleases. J Natl Cancer Inst Monogr. 2008; (39):20-4.
View in:
PubMed
Formation of NHEJ-derived reciprocal chromosomal translocations does not require Ku70. Nat Cell Biol. 2007 Aug; 9(8):978-81.
View in:
PubMed
Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant. 2007 Sep; 40(5):481-6.
View in:
PubMed
Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2007 May; 13(5):615-21.
View in:
PubMed
Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1096-7.
View in:
PubMed
Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy. Clin Infect Dis. 2006 Nov 01; 43(9):e92-4.
View in:
PubMed
Modeling oncogenic translocations: distinct roles for double-strand break repair pathways in translocation formation in mammalian cells. DNA Repair (Amst). 2006 Sep 08; 5(9-10):1065-74.
View in:
PubMed
Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther. 2006 Jun; 4(3):457-68.
View in:
PubMed
Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant. 2006 Mar; 37(6):539-46.
View in:
PubMed
Adamantane resistance in influenza A. JAMA. 2006 Feb 22; 295(8):934-6.
View in:
PubMed
Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Methods Enzymol. 2006; 409:524-40.
View in:
PubMed
Alternative pathways for the repair of RAG-induced DNA breaks. Mol Cell Biol. 2006 Jan; 26(1):131-9.
View in:
PubMed
Active tuberculosis limited to foreign-born patients after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2005 Oct; 36(8):741-3.
View in:
PubMed
A model of oncogenic rearrangements: differences between chromosomal translocation mechanisms and simple double-strand break repair. Blood. 2006 Jan 15; 107(2):777-80.
View in:
PubMed
New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opin Pharmacother. 2005 Aug; 6(10):1669-79.
View in:
PubMed
Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol. 2004 Jul; 25(7):603-8.
View in:
PubMed
High rates of infection and colonization by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003 Jun; 31(11):1015-21.
View in:
PubMed
Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003 Feb 27; 348(9):867-8.
View in:
PubMed
Nosocomial central venous catheter infections among patients with different types of cancer. Infect Control Hosp Epidemiol. 2002 May; 23(5):234-5.
View in:
PubMed
Rhodococcus equi: an emerging pathogen. Clin Infect Dis. 2002 May 15; 34(10):1379-85.
View in:
PubMed
A comparison of verbal fluency tasks in schizophrenic patients and normal controls. Schizophr Res. 2001 Sep 01; 51(2-3):119-26.
View in:
PubMed
Risk for tuberculosis infection among internally displaced persons in the Republic of Georgia. Int J Tuberc Lung Dis. 2001 Feb; 5(2):164-9.
View in:
PubMed
Control of influenza A on a bone marrow transplant unit. Infect Control Hosp Epidemiol. 2000 Nov; 21(11):730-2.
View in:
PubMed
Rotavirus outbreak on a pediatric oncology floor: possible association with toys. Am J Infect Control. 2000 Oct; 28(5):378-80.
View in:
PubMed
Hepatitis C in an urban population infected with the human immunodeficiency virus. AIDS. 1999 Dec 24; 13(18):2593-5.
View in:
PubMed
Seroconversion rates in healthcare workers using a latex agglutination assay after varicella virus vaccination. Infect Control Hosp Epidemiol. 1999 Jul; 20(7):504-7.
View in:
PubMed
Comparison of plasma prothrombin and factor VII and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase. Am J Hematol. 1998 Mar; 57(3):193-9.
View in:
PubMed